Objective.-To determine the incidence of acute mountain sickness (AMS), the frequency of summiting success, and the factors that affect these in trekkers on Kilimanjaro, one of the world's most summitted high-altitude peaks.
Introduction
Mt Kilimanjaro, the highest mountain in Africa (5895 m), is a popular tourist destination and perhaps the most climbed high-altitude peak in the world, with at least 30 000 trekkers attempting it each year. 1, 2 All visitors to high altitude risk developing acute mountain sickness (AMS). Mt Kilimanjaro is regarded as the highest freestanding mountain in the world, rising directly from a lowland plateau with no foothills, and unlike trekking routes in the Himalayas and Andes, it is easily accessed from an international airport located less than 40 km away. Consequently, climbers face poor acclimatization and high rates of AMS. This is compounded by an ascent route that involves no technical climbing and by the mountain's fame as one of the continental ''seven summits'' (the highest mountain in one of the 7 continents); thus, many professional trekking companies market Mt Kilimanjaro as ''a challenge of a lifetime,'' and, indeed, for many people it is. As a result of these factors it is often ascended by relatively inexperienced trekkers and is frequently used to raise money for charities.
While several routes exist up the mountain, the most popular is the Marango Route, colloquially known as the ''Coca-Cola Route''; most trekkers take 4 or 5 days to ascend from the Tanzanian lowlands (,1500 m) to the summit. This contravenes established advice that a slow ascent is favorable, and once above 3000 m an individual should not ascend more than 300 to 600 m in a 24-hour period, with occasional rest days in addition. 3, 4 Other routes take 6 to 8 days to ascend the mountain, but a combination of factors makes them less popular. Trekkers must stay in tents rather than the huts that exist on the Marango Route, which carries a perceived relative lack of comfort as well as the extra costs involved in carrying this equipment. The current cost of National Park fees and accommodation are US$110 per day, making longer routes significantly more expensive. Finally, many trekkers incorporate the ascent of this mountain into a busy holiday schedule that includes visiting such regional attractions as the safari and the Indian Ocean beaches.
All visitors to high altitude are at risk of illness, notably AMS, high-altitude cerebral edema, and highaltitude pulmonary edema, and there is an abundance of literature [5] [6] [7] on AMS and altitude-related pathology. However, there is little work specifically on Mt Kilimanjaro with its unique ascent profile. 8 Hypoxemia is thought to be central to the development of AMS (reviewed in Hackett and Roach 5 and Basnyat and Murdoch 6 ), and low arterial oxygen saturation is associated with AMS, both on acute 9 and long-tem exposure to hypoxia. 10 Trekking companies on Mt Kilimanjaro are now making basic physiological measurements, such as arterial oxygen saturation (SaO 2 ), to educate their clients.
The efficacy of acetazolamide for pharmacologic prophylaxis of AMS is well established. 11 Mechanisms underlying its benefit are complex and incompletely understood, but they include improved arterial oxygen saturation (by increasing minute ventilation) and increased diuresis. 12, 13 We hypothesized that the incidence and intensity of AMS would be decreased and summit success increased by an extra day of acclimatization and also by use of acetazolamide. We hypothesized that trekkers with lower SaO 2 were less likely to reach the summit. and those whose command of English was not sufficient to give consent were excluded from the study.
Methods
All participants ascended by the Marango Route, upon which trekkers stayed at fixed huts on their ascent: all stayed for 1 night each at 2700 m, 3700 m, and 4700 m, and some had an extra (second) overnight stop at 3700 m. All trekkers then attempted the summit (5895 m) and stopped at 3700 m on descent. Researchers were stationed on the mountain at each of the 3 huts simultaneously.
All trekkers attempting the summit were recruited at the first hut on their ascent (2700 m). Written informed consent was obtained, and trekkers were asked to report to a researcher each evening while on the mountain, during both ascent and descent, when the incidence of AMS and its intensity was determined using the Lake Louise Score (LLS).
14 As used by others, a score of $4, including headache, was used to define the presence of AMS. 15 Acute mountain sickness on the summit day was determined retrospectively at 4700 m on descent.
Body mass index was determined as weight (kg)/height 2 (m); SaO 2 was determined using a pulse oximeter (Nellcor N-20PA, Tyco Healthcare, Swindon, UK). Blood pressure was measured using a portable monitor (M10-IT model, Omron-Healthcare, Henfield, UK). Mean arterial pressure was calculated as diastolic pressure + M 3 (systolic pressure 2 diastolic pressure). Heart rate (beats/min) and respiratory rate (breaths/min) were also measured. The average of 3 readings was taken for physiological variables, after a minimum of 30 minutes at rest.
DATA ANALYSIS
Results were analysed using SPSS version 14. MannWhitney U test with the Bonferroni correction was used to determine differences in physiological variables and mean AMS scores. A x 2 test was used to determine differences in summiting success and AMS incidence.
Results
During the study 350 trekkers were approached, of which 312 agreed to participate. Thirty-one trekkers were excluded from the study because of recent altitude exposure or because they had type 1 diabetes mellitus (the latter group used a longer ascent profile 16 ). One hundred trekkers (66 male) of the remaining 281 were lost to follow-up during the study. After these losses, 181 complete sets of data from trekkers who attempted the summit were available for analysis. These were subdivided into different groups: those who spent 4 days ascending the mountain (4-day ascent profile) and those who spent an extra night at 3700 m to acclimatize (5-day ascent profile); and those who took acetazolamide during their ascent and those who did not. Of 181 trekkers who completed the study, 54 were taking prophylactic acetazolamide in doses ranging from 250 to 750 mg daily. Physical characteristics (height 173 6 10 cm, weight 70.1 6 30.1 kg, age 32.3 6 12.2 years) were not different between those lost from follow-up and those completing the study, between those on the 2 ascent routes, or between those who were either taking or not taking acetazolamide (data not shown). Figure 1 shows the rate at which trekkers were lost from the study and the division between the 5-day group and the 4-day group.
TREKKERS NOT TAKING ACETAZOLAMIDE

Ascent route
An extra day of acclimatization made no difference to summit success (27/41 on 4-day route [66%] vs 43/86 [50%] on the 5-day route; P 5.09; Table 1 ).
Physical characteristics and physiology
No differences in age or body mass index were found between successful and unsuccessful trekkers. After adjusting for multiple comparisons (Bonferroni), no difference in physiology was found between successful and unsuccessful trekkers on either the 4-or 5-day ascent profile routes (Table 2) .
Acute mountain sickness
Acute mountain sickness intensity (LLS score) rose with increasing altitude (Figure 2 ). Scores were not different between trekkers on 4-day and 5-day ascent profiles. There was variation in AMS intensity (eg, at 4700 m scores ranged from 0 to 11 and on the summit day from 0 to 21). Figure 1 . Schematic of subject progression up Mt Kilimanjaro. The 2 ascent profiles (4-day ascent and 5-day ascent) were not equally used, and loss to follow-up occurred at each stage. Of the 281 trekkers recruited, 241 were followed up at 3700 m, of which 148 spent a second night at this altitude (5 days). One hundred and forty-three of the 5-day cohort were followed up at 4700 m and 117 on summit day. On the 4-day route 79 were followed up at 4700 m, of which 64 were seen on the summit day. The presence of AMS (LLS $ 4) had no influence on summit success in trekkers on both the 4-day and 5-day ascent profiles. Acute mountain sickness incidence was significantly higher on the summit day in those on the 4-day ascent profile compared with trekkers on the 5-day ascent profile (37/41 [90%] vs 61/86 [71%]; P 5 .02; Table 3 ).
Trekkers taking acetazolamide
Summit success and ascent route
In trekkers taking acetazolamide, the extra day of acclimatization improved summit success from 14/23 (61%) to 27/31 (87%, P 5 .03). {AZ indicates acetazolamide; Age in years; BMI, body mass index; SaO 2 , arterial oxygen saturation %; HR, heart rate in beats per minute; RR, respiratory rate in breaths per minute; and MAP, mean arterial pressure in mm Hg.
{No differences significant at P , .008 (Bonferroni adjusted). 
Physical characteristics and physiology
No differences in physical (age, body mass index) or physiological (heart rate, respiratory rate, mean arterial pressure, SaO 2 ) variables were seen between successful and unsuccessful trekkers (Table 2 ). Higher SaO 2 was seen in comparing trekkers taking acetazolamide to those not taking acetazolamide (Table 2) .
Acute mountain sickness
Significantly lower LLS scores were seen in trekkers taking acetazolamide compared with trekkers not taking acetazolamide on the 5-day ascent profile at both 3700 m (1.1 vs 2.0; P 5 .02) and 4700 m (1.9 vs 3.0; P 5 .04; Figure 2 ). 
COMORBIDITIES
The cohort included several trekkers with comorbidities. Six trekkers had treated hypertension, of which 3 (50%) made it to the summit (none taking acetazolamide, all on 4-day ascent route). Ten trekkers followed up on summit day had asthma, 4 on the 4-day ascent route and 6 on the 5-day route, including 4 trekkers on acetazolamide. Five (50%) achieved the summit (3 on the 4-day route and 2 on the 5-day route). 17 Two out of 4 asthmatic trekkers taking acetazolamide achieved the summit (1 on the 4-day route and 1 on the 5-day route).
ENTIRE COHORT ANALYSIS
The success rate for the entire cohort achieving the summit was 111/181 (61.3%). For those who did not succeed in reaching the summit, 29/181 (16.0%) stopped at Gilmans' Point (5600 m) on the summit crater rim but 1.5 hours walk to the summit, 26/181 (14.4%) descended at various points between setting off from 4700 m and 5600 m (Gilmans' Point), while 15/181 (8.3%) failed to leave the final hut at 4700 m. The overall incidence of AMS during the summit attempt day was 139/181 (77%).
Discussion
The main findings of the study are as follows:
1. There is a high incidence of AMS on Mt Kilimanjaro; 2. Many trekkers will be unsuccessful in reaching the summit; and Table 3 . 3. Acetazolamide improves summit success and reduces the incidence and intensity of AMS, but only for those on a slower ascent profile.
The incidence of AMS for all trekkers was 77%, which is among the highest incidence rates of any trekking location in the world. In addition, only 61% of trekkers reached the summit (5895 m). This is comparable to an observational study 18 that found an AMS incidence of 75% among Finnish trekkers ascending Mt Kilimanjaro. In the same study only 53% of trekkers reached 5600 m (Gilmans' Point). Other studies found an incidence of 60% on Mt Damavand (5671 m, Iran), 19 68% in Gosaikund Lake (4300 m, Nepal), 20 and 92% at 5500 m in Peru. 21 Acute mountain sickness, high-altitude pulmonary edema, and high-altitude cerebral edema are potentially fatal diseases that are avoidable with appropriate preparation. Kilimanjaro Christian Medical Centre (the nearest hospital to the mountain) reported 25 tourist deaths on Kilimanjaro between January 1996 and October 2003, 14 of which were attributable to highaltitude illnesses, 2 although we saw no cases of highaltitude pulmonary edema or high-altitude cerebral edema among our study population. No figures were available for porters.
In those not taking acetazolamide, the choice of ascent profile did not affect summit success. The 5-day cohort, which took an extra day for acclimatization, actually had a lower success rate than did those trekkers on the 4-day route. It is possible that they were a more cautious group who were willing to turn around on summit day with early signs of AMS.
An acclimatization day at 3700 m was associated with lower AMS incidence on summit day, although this incidence rate was still high (72% vs 86%, trekkers with and without acetazolamide, respectively). The lack of flexibility in route choice coupled with branding of the Marango Route as ''easy'' is dangerous and disappointing for many trekkers. There are several routes up Mt Kilimanjaro that take longer than 5 days, with a gentler ascent profile and better acclimatization. Anecdotal information from trekking companies indicated success rates of .95% on the Western Breach Route, on which trekkers typically ascend over 6 days or more (oral communication Kilitreks Tour operator, 2005).
Overall, the lowest incidence of AMS and the highest rate of summit success were in trekkers on the 5-day ascent profile who were taking acetazolamide. Acetazolamide is effective in reducing the symptoms of AMS, and it is a useful adjunct for high-altitude visits. 22, 23 We did not record trekkers' dosages or compliance, although it was clear that use of this drug had a measurable benefit in terms of both AMS incidence and chance of summiting. However, even in those taking acetazolamide, levels of AMS were still high, and side effects can be unpleasant (including diuresis and paresthesia 4 ). Its use is a matter of individual choice, but acetazolamide is not a substitute for good acclimatization. Our research group of 7 spent 16 days on the mountain before achieving 100% summit success with 0% AMS incidence.
One strength of our study was the Marango Route, selected because the rapid ascent produces a high incidence of AMS and allows researchers to follow trekkers at regular intervals. Additionally, the population has little previous acclimatization experience; only 10% of trekkers had visited high altitude in the previous 2 weeks, and the whole group is representative of a general trekking population (rather than comprising elite mountaineers). However, our study does have weaknesses, mainly relating to inevitable logistic problems of such fieldwork. One hundred trekkers were lost to follow-up during the study. Some of these may have chosen to descend or withdraw from the study as a result of AMS, which might have caused an underestimate of the presence of AMS and an overestimate of summit success.
Our study highlights areas for future work. There is still uncertainty over the optimal acetazolamide dosing regime. We did not find differences in physiological variables, easily measured on the mountain, between those who succeeded and those who failed to summit. Measurements are being taken by some climbing companies to provide information for their clients, but further investigation is needed if recommendations on continuation of the trek are to be made based on these measurements. We were unable to examine the porters who work on this mountain. The International Porter Protection Group 24 can provide more information on the problems they encounter.
The vast majority of trekkers had a thoroughly enjoyable experience climbing Mt Kilimanjaro, and most healthy individuals should be able to reach the summit. People should take this ascent seriously, either by taking one of the longer routes up the mountain or by acclimatizing on nearby peaks such as Mt Meru (4566 m) or Mt Kenya (5199 m).
